Fig. 3.

Tornado plots showing results of one-way sensitivity analysis for ranibizumab compared with a vPDT and b observation. The X axis represents the net monetary benefit, which for the base-case scenario is £9,289 for ranibizumab versus vPDT, and £6,013 for ranibizumab versus observation. Parameters varied are listed in the Y axis. Low value, lower limit of parameter varied for sensitivity analysis; high value, upper limit of parameter varied for sensitivity analysis; multiplier, multiplication factor for base-case value of parameter. BSE better-seeing eye, vPDT verteporfin photodynamic therapy, WSE worse-seeing eye